ICER pilot project to use real-world evidence in hereditary angioedema treatments value assessment update


The Institute for Clinical and Economic Review (ICER; MA, USA) has announced it is to update its 2018 value assessment concerning three treatments indicated for long-term prophylaxis against hereditary angioedema attacks. ICER is to incorporate observational real-world evidence, analyzed using the Aetion Evidence Platform®, in the new pilot, to help further clarify the value of the therapies. In November 2018, ICER released a final Evidence Report concerning the comparative clinical and cost–effectiveness of three therapies indicated for long-term prophylaxis against hereditary angioedema attacks; the agents reviewed in the report were lanadelumab (Takhzyro®, Takeda, Tokyo, Japan), Haegarda® (CSL Behring, PA, USA)...

To view this content, please register now for access

It's completely free